→ Takeda has cleared another hurdle for the Shire buyout that would make it one of the world’s 10 biggest pharma companies. The fair trade commission in Japan — Takeda’s ancestral home — has granted “unconditional clearance” for the acquisition, joining antitrust regulators in the US, China and Brazil. The EU has yet to give its final decision, which is expected in November. “Takeda is proud of its Japanese heritage, and we are looking forward to building on this heritage as a combined company to continue delivering highly-innovative medicines that are transformative to patients in Japan and around the world,” said CEO Christophe Weber, whose globalization strategy has been meeting some high-profile pushback from traditionalists at the company.
→ European and Asian investors have convened to infuse €15.3 million ($17.6 million) into Paris-based Acticor Biotech. Their pitch for the Series B centered around lead candidate ACT017, an anti-blood clot treatment for acute ischemic stroke that will now go into its first Phase II. It won over Belgium VC fund Newton BioCapital, Korea’s Mirae Capital, and two Hong Kong-based funds — CMS Medical Venture Investment and A&B. CapDecisif Management and other existing backers also participated.
→ Cancer diagnostics company Exact Sciences $EXAS is bringing Biomatrica into its fold after years of using its sample preservation services. As a subsidiary of Exact Sciences, which is based in Madison, WI, Biomatrica will keep its offices in San Diego and continue to supply tubes and technologies to other biotech clients.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,000+ biopharma pros who read Endpoints News by email every day.Free Subscription